Skip to main content
SpringerLink
Log in

Diagnosis of Myeloproliferative Neoplasms: Current Perspectives from Recent Research

  • Chapter
  • First Online:
Hematopathology

Abstract

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues, 2017 revised edition, representing the most recent update of the customarily amended classification, last updated in 2008, has recently been published [1]. Since the last edition, there has been tremendous advancement in the basic understanding of disease pathobiology, leading to the discovery of newer biomarkers. This has impacted the diagnostic criteria in the myeloproliferative neoplasm (MPN) category significantly [1, 2]. Majority of the voluminous information has been obtained from research based on the gene expression analysis and next-generation sequencing (NGS) [3–8]. Nevertheless, this newer 2017 classification retains the basic approach hinged on clinical characteristics, morphological features, immunophenotype, and cytogenetics (CTG). This highlights a consensus of opinion and expertise recommendation from different hematopathologists, clinical hematologists and also from other branches related to hematology like oncologists and geneticists [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017.

    Google Scholar 

  2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.

    Google Scholar 

  3. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405.

    Article  CAS  Google Scholar 

  4. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90.

    Article  CAS  Google Scholar 

  5. Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, et al. Molecular diagnostics of myeloproliferative neoplasms. Eur J Haematol. 2015;95:270–9.

    Article  CAS  Google Scholar 

  6. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127:325–32.

    Article  CAS  Google Scholar 

  7. Kim Y, Park J, Jo I, Lee GD, Kim J, Kwon A, et al. Genetic–pathologic characterization of myeloproliferative neoplasms. Exp Mol Med. 2016;48:e247.

    Article  CAS  Google Scholar 

  8. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Beau MML, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    Article  CAS  Google Scholar 

  9. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112:2190–8.

    Article  CAS  Google Scholar 

  10. Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2014;2014:287–96.

    Article  Google Scholar 

  11. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22.

    Article  CAS  Google Scholar 

  12. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J. 2015;5:e337.

    Article  CAS  Google Scholar 

  13. Skoda RC, Duek A, Grisouard J. Pathogenesis of myeloproliferative neoplasms. Exp Hematol. 2015;43:599–608.

    Article  CAS  Google Scholar 

  14. Malherbe JAJ, Fuller KA, Arshad A, Nangalia J, Romeo G, Hall SL, et al. Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms. J Clin Pathol. 2016;69:155–63.

    Article  CAS  Google Scholar 

  15. Ha J-S, Kim Y-K. Calreticulin exon 9 mutations in myeloproliferative neoplasms. Ann Lab Med. 2015;35:22–7.

    Article  CAS  Google Scholar 

  16. Wang X, Haylock D, Hu CS, Kowalczyk W, Jiang T, Qiu J, et al. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. Blood. 2016;127:3398–409.

    Article  CAS  Google Scholar 

  17. Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients: type 1 vs. type 2 CALR mutations in ET. Am J Hematol. 2014;89:E121–4.

    Article  CAS  Google Scholar 

  18. Grinfeld J, Nangalia J, Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica. 2017;102:7–17.

    Article  CAS  Google Scholar 

  19. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014;28:1407–13.

    Article  CAS  Google Scholar 

  20. De Freitas RM, da Costa Maranduba CM. Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview. Rev Bras Hematol Hemoter. 2015;37:348–53.

    Google Scholar 

  21. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood. 2008;112:844–7.

    Article  CAS  Google Scholar 

  22. Cabagnols X, Defour J-P, Ugo V, Ianotto JC, Mossuz P, Mondet J, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Blood. 2014;124:1823.

    Google Scholar 

  23. Shammo JM, Stein BL. Mutations in MPNs: prognostic implications, window to biology, and impact on impact on treatment decisions. Hematology Am Soc Hematol Educ Program. 2016;2016(1):552–60.

    Article  Google Scholar 

  24. Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaemmanuil E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 2015;29:66–75.

    Article  CAS  Google Scholar 

  25. Pardanani A, Lasho T, Laborde R, Elliott M, Hanson C, Knudson R, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27:1870–3.

    Article  CAS  Google Scholar 

  26. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368:1781–90.

    Article  CAS  Google Scholar 

  27. Ouyang Y, Qiao C, Chen Y, Zhang S-J. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia. Oncotarget. 2017;8:20834–41.

    PubMed  PubMed Central  Google Scholar 

  28. Passamonti F, Maffioli M. Update from the latest WHO classification of MPNs: a user’s manual. Hematology Am Soc Hematol Educ Program. 2016;2016(1):534–42.

    Article  Google Scholar 

  29. Plo I, Bellanné-Chantelot C, Mosca M, Mazzi S, Marty C, Vainchenker W. Genetic alterations of the thrombopoietin/MPL/JAK2 axis impacting megakaryopoiesis. Front Endocrinol. 2017;8:234. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600916/.

  30. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366.

    Article  CAS  Google Scholar 

  31. Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M, et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia. 2014;28:1811–8.

    Article  CAS  Google Scholar 

  32. Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018. J Natl Compr Cancer Netw. 2017;15:1193–207.

    Article  Google Scholar 

  33. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.

    Article  CAS  Google Scholar 

  34. Bauer S, Romvari E. Interpreting molecular monitoring results and international standardization in chronic myeloid Leukemia. J Adv Pract Oncol. 2012;3:151–60.

    PubMed  PubMed Central  Google Scholar 

  35. Shivarov V, Ivanova M, Yaneva S, Petkova N, Hadjiev E, Naumova E. Quantitative bead-based assay for detection of JAK2 exon 12 mutations. Leuk Lymphoma. 2013;54:1343–4.

    Article  CAS  Google Scholar 

Download references

Conflict of Interest

Nil.

Author information

Authors and Affiliations

  1. Department of Pathology, JIPMER, Puducherry, India

    Prabhu Manivannan & Hema Subramanian

Authors
  1. Prabhu Manivannan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hema Subramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prabhu Manivannan .

Editor information

Editors and Affiliations

  1. Department of Hematology, All India Institute of Medical Sciences, New Delhi, India

    Renu Saxena

  2. Department of Hematology, All India Institute of Medical Sciences, New Delhi, India

    Hara Prasad Pati

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Manivannan, P., Subramanian, H. (2019). Diagnosis of Myeloproliferative Neoplasms: Current Perspectives from Recent Research. In: Saxena, R., Pati, H. (eds) Hematopathology. Springer, Singapore. https://doi.org/10.1007/978-981-13-7713-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-7713-6_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-7712-9

  • Online ISBN: 978-981-13-7713-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation